Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Share-based Compensation (2018 - 2025)

10x Genomics' Share-based Compensation history spans 8 years, with the latest figure at $25.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 22.5% year-over-year to $25.2 million; the TTM value through Dec 2025 reached $109.1 million, down 22.47%, while the annual FY2025 figure was $109.1 million, 22.47% down from the prior year.
  • Share-based Compensation for Q4 2025 was $25.2 million at 10x Genomics, roughly flat from $25.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $45.7 million in Q2 2023 and bottomed at $16.2 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $33.0 million (2022), against an average of $32.5 million.
  • The largest annual shift saw Share-based Compensation soared 140.79% in 2021 before it fell 28.4% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $26.9 million in 2021, then soared by 52.3% to $41.0 million in 2022, then fell by 5.02% to $38.9 million in 2023, then fell by 16.39% to $32.5 million in 2024, then dropped by 22.5% to $25.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Share-based Compensation are $25.2 million (Q4 2025), $25.3 million (Q3 2025), and $27.6 million (Q2 2025).